Law360, New York (August 7, 2015, 8:43 PM EDT) -- A landmark court decision on Friday allowing truthful and nonmisleading off-label promotion by Amarin Pharma Inc. provides a roadmap for drugmakers to market products more freely, but attorneys say much uncertainty remains about the ruling's impact on criminal misbranding cases and False Claims Act litigation. Here are five questions raised by Amarin’s victory.
Will the FDA Appeal?
The most immediate question is whether the U.S. Food and Drug Administration will appeal to the Second Circuit, which issued the 2012 ruling in U.S. v. Caronia that was...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.